-
Posted: March 29th, 2010, 2:00am CDT
A new study from Iowa State University's Nutrition and Wellness Research Center (NWRC) may give men a way to combat high cholesterol without drugs -- if they don't mind sprinkling some flaxseed into their daily diet. Suzanne Hendrich, an ISU professor in food science and human nutrition, led a study that examined the effects of flaxseed lignan in 90 people diagnosed with high cholesterol...
-
Posted: March 23rd, 2010, 11:00pm CDT
A March 19 article in Time Magazine about the use of statins in women and a recent statement from the U.S. Food and Drug Administration (FDA) about the use of simvastatin in men and women have addressed both the benefits and side effects of statin therapy for elevated cholesterol values administered in an effort to reduce the risk of heart disease and stroke...
-
Posted: March 23rd, 2010, 2:00am CDT
CTD Holdings, Inc. (OTCBB: CTDH) (FRANKFURT: CDJ) announced that a significant order has been placed by a Brazilian healthcare organization for Trappsol Cyclo™ for the experimental treatment of Niemann Pick Type C (NPC) disease...
-
Posted: March 21st, 2010, 2:00am CDT
The U.S. Food and Drug Administration warned patients and healthcare providers about the potential for increased risk of muscle injury from the cholesterol-lowering medication Zocor (simvastatin) 80 mg...
-
Posted: March 20th, 2010, 4:00am CDT
Niacin, or nicotinic acid, when used under the care and monitoring of a healthcare provider, is the most effective agent available for increasing high-density lipoprotein (HDL), or "good cholesterol (1)." HDL is known as "good cholesterol" because it has protective effects on the heart and blood vessels...
-
Posted: March 17th, 2010, 5:00am CDT
Cardiovascular risk can be reduced by an additional 31 percent in type 2 diabetes patients with atherogenic dyslipidemia, the common combination of elevated triglycerides (TG, 204 mg/dL or 2.3 mmol/L or higher) and low levels of high-density lipoprotein cholesterol (HDL-C, 34 mg/dL or 0.88 mmol/L or lower). This is achieved by adding fenofibrate to simvastatin...
-
Posted: March 17th, 2010, 3:00am CDT
Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) today announced that data from a phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were published in The Lancet. This study met its primary endpoint, resulting in an average LDL-C reduction of greater than 100 mg/dL in this very high-risk patient population...
-
Posted: March 17th, 2010, 2:00am CDT
Impax Laboratories, Inc. (NASDAQ: IPXL) confirms that it has initiated a challenge of the patent listed by Abbott Laboratories and Fournier Laboratories Ireland Ltd. in connection with its TRILIPIX® (choline fenofibrate) delayed-release capsules, 135 mg and 45 mg...
-
Posted: March 12th, 2010, 7:00pm CST
People whose "bad" cholesterol and risk of future heart disease stay too high despite cholesterol-lowering statin therapy can safely lower it by adding a drug that mimics the action of thyroid hormone. In a report published in the Mar...
-
Posted: March 12th, 2010, 3:00am CST
An experimental thyroid drug reduces cholesterol without the troublesome side effects experienced by some people on statins, according to a study published today in The New England Journal of Medicine...
-
Posted: March 12th, 2010, 2:00am CST
Only half of all patients at high risk of heart disease are given correct targets for lowering their cholesterol levels according to a study of 25,250 patients in Germany published online 11 March in the European Heart Journal [1]...
-
Posted: March 12th, 2010, 2:00am CST
A thyroid-hormone-like substance that works specifically on the liver reduces blood cholesterol with no serious side effects. This according to a clinical trial conducted by researchers from the Swedish medical university Karolinska Institutet, amongst other centres, published in the top-ranking scientific periodical The New England Journal of Medicine...
-
Posted: March 11th, 2010, 10:00pm CST
The Swedish biotech company Karo Bio (Reuters: KARO.ST) announced the publication of results from a clinical phase II trial evaluating the company's liver selective thyroid hormone receptor agonist eprotirome and its ability to further reduce serum LDL cholesterol levels in statin-treated patients...
-
Posted: March 11th, 2010, 5:00am CST
A new drug, eprotirome, has been shown to significantly lower bad cholesterol, triglycerides and Lp(A), without the side effects that statins cause in many people. Results of a study were published in the New England Journal of Medicine. "Our study has shown a dramatic reduction in the dangerous fats that cause heart disease, the number one killer of Americans," said Dr...
-
Posted: March 11th, 2010, 5:00am CST
People whose "bad" cholesterol and risk of future heart disease stay too high despite cholesterol-lowering statin therapy can safely lower it by adding a drug that mimics the action of thyroid hormone. In a report published in the Mar...
-
Posted: March 11th, 2010, 4:00am CST
Purchases of cholesterol and diabetes prescription drugs by elderly Medicare beneficiaries reached nearly $19 billion in 2007 - about one-fourth of the approximately $82 billion spent for medications for the elderly, according to the latest AHRQ News and Numbers...
-
Posted: March 9th, 2010, 7:00am CST
A research team from the Laval Centre de sante et de services sociaux, Universite de Montreal and McGill University Health Centre has examined the benefits of greater collaboration between family physicians and community pharmacists for select patients...
-
Posted: March 9th, 2010, 4:00am CST
The collection of symptoms that is the metabolic syndrome - insulin resistance, high cholesterol, fatty liver, and a greater risk for diabetes, heart disease, and stroke - are all related to obesity, but, according to a review in the March 9th issue of the Cell Press publication Trends in Endocrinology and Metabolism, not in the way you probably think they are...
-
Posted: March 2nd, 2010, 7:00am CST
Simvastatin might help us control our cholesterol, but when it comes to infection, it's an entirely different story says a new research study published in the Journal of Leukocyte Biology (http://www.jleukbio.org). In the research report, scientists from Italy show that simvastatin delivers a one-two punch to the immune system...